Literature DB >> 16545521

Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states.

S K Joshi1, Joseph P Mikusa, Gricelda Hernandez, Scott Baker, Char-Chang Shieh, Torben Neelands, Xu-Feng Zhang, Wende Niforatos, Karen Kage, Ping Han, Douglas Krafte, Connie Faltynek, James P Sullivan, Michael F Jarvis, Prisca Honore.   

Abstract

Antisense (AS) oligodeoxynucleotides (ODNs) targeting the Nav 1.8 sodium channel have been reported to decrease inflammatory hyperalgesia and L5/L6 spinal nerve ligation-induced mechanical allodynia in rats. The present studies were conducted to further characterize Nav 1.8 AS antinociceptive profile in rats to better understand the role of Nav 1.8 in different pain states. Consistent with earlier reports, chronic intrathecal Nav 1.8 AS, but not mismatch (MM), ODN decreased TTX-resistant sodium current density (by 60.5+/-10.2% relative to MM; p<0.05) in neurons from L4 to L5 dorsal root ganglia and significantly attenuated mechanical allodynia following intraplantar complete Freund's adjuvant. In addition, 10 days following chronic constriction injury of the sciatic nerve, Nav 1.8 AS, but not MM, ODN also attenuated mechanical allodynia (54.3+/-8.2% effect, p<0.05 vs. MM) 2 days after initiation of ODN treatment. The anti-allodynic effects remained for the duration of the AS treatment, and CCI rats returned to an allodynic state 4 days after discontinuing AS. In contrast, Nav 1.8 AS ODN failed to reduce mechanical allodynia in the vincristine chemotherapy-induced neuropathic pain model or a skin-incision model of post-operative pain. Finally, Nav 1.8 AS, but not MM, ODN treatment produced a small but significant attenuation of acute noxious mechanical sensitivity in naïve animals (17.6+/-6.2% effect, p<0.05 vs. MM). These data demonstrate a greater involvement of Nav 1.8 in frank nerve injury and inflammatory pain as compared to acute, post-operative or chemotherapy-induced neuropathic pain states.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545521     DOI: 10.1016/j.pain.2006.02.011

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  75 in total

Review 1.  Na(+) channel blockers for the treatment of pain: context is everything, almost.

Authors:  Michael S Gold
Journal:  Exp Neurol       Date:  2007-12-08       Impact factor: 5.330

Review 2.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

3.  Exon 11 skipping of SCN10A coding for voltage-gated sodium channels in dorsal root ganglia.

Authors:  Jana Schirmeyer; Karol Szafranski; Enrico Leipold; Christian Mawrin; Matthias Platzer; Stefan H Heinemann
Journal:  Channels (Austin)       Date:  2014       Impact factor: 2.581

Review 4.  Breaking barriers to novel analgesic drug development.

Authors:  Ajay S Yekkirala; David P Roberson; Bruce P Bean; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2017-06-09       Impact factor: 84.694

5.  A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain.

Authors:  Boris Tabakoff; Wenhua Ren; Lauren Vanderlinden; Lawrence D Snell; Christopher J Matheson; Ze-Jun Wang; Rock Levinson; C Thetford Smothers; John J Woodward; Yumiko Honse; David Lovinger; Anthony M Rush; William A Sather; Daniel L Gustafson; Paula L Hoffman
Journal:  Eur J Pharmacol       Date:  2016-05-05       Impact factor: 4.432

6.  Structural determinants of drugs acting on the Nav1.8 channel.

Authors:  Liam E Browne; Frank E Blaney; Shahnaz P Yusaf; Jeff J Clare; Dennis Wray
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

7.  PKCepsilon-dependent potentiation of TTX-resistant Nav1.8 current by neurokinin-1 receptor activation in rat dorsal root ganglion neurons.

Authors:  Chun-Lei Cang; Hua Zhang; Yu-Qiu Zhang; Zhi-Qi Zhao
Journal:  Mol Pain       Date:  2009-06-30       Impact factor: 3.395

8.  Blockade of Nav1.8 currents in nociceptive trigeminal neurons contributes to anti-trigeminovascular nociceptive effect of amitriptyline.

Authors:  Jingyao Liang; Xiaoyan Liu; Meiyan Pan; Wei Dai; Zhao Dong; Xiaolin Wang; Ruozhuo Liu; Jianquan Zheng; Shengyuan Yu
Journal:  Neuromolecular Med       Date:  2013-11-30       Impact factor: 3.843

9.  Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats.

Authors:  Tufan Mert; Yasemin Gunes
Journal:  J Am Assoc Lab Anim Sci       Date:  2012       Impact factor: 1.232

10.  A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.

Authors:  Michael F Jarvis; Prisca Honore; Char-Chang Shieh; Mark Chapman; Shailen Joshi; Xu-Feng Zhang; Michael Kort; William Carroll; Brian Marron; Robert Atkinson; James Thomas; Dong Liu; Michael Krambis; Yi Liu; Steve McGaraughty; Katharine Chu; Rosemarie Roeloffs; Chengmin Zhong; Joseph P Mikusa; Gricelda Hernandez; Donna Gauvin; Carrie Wade; Chang Zhu; Madhavi Pai; Marc Scanio; Lei Shi; Irene Drizin; Robert Gregg; Mark Matulenko; Ahmed Hakeem; Michael Gross; Matthew Johnson; Kennan Marsh; P Kay Wagoner; James P Sullivan; Connie R Faltynek; Douglas S Krafte
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.